Cytori Therapeutics, Inc. CYTX will webcast their corporate presentation at the Biotech Showcase™ at 11:30 AM PT (2:30 PM ET) on Tuesday, January 8. The presentation will be held in the Powell Room of the Parc 55 Wyndham Hotel in San Francisco.
The presentation webcast may be accessed on the "Webcasts" page of the Investor Relations section of the Company's website. The webcast can be accessed live and will be available for replay approximately one hour after the presentation on the Company's website.
In addition, Cytori's CEO Chris Calhoun will be participating on the Alliance for Regenerative Medicine's (ARM) State of the Industry panel. The panel discussion will be filmed and will be made available at a later date on the ARM website. The details are as follows:
January 8, 2013
|Time:||8:00 – 10:00 AM PT|
|Location:||Parc 55 Wyndham, 55 Cyril Magnin Street, San Francisco, CA|
|Level 2 – Divisadero Room|
About Biotech Showcase™:
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its fifth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft® products are available in North America and Europe for fat grafting procedures. www.cytori.com
Cytori Therapeutics, Inc.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.